Carlsberg spinout Traitomic raises €20m led by Sofinnova to take non-GM traits to the US and Australia


Traitomic, a Copenhagen company that grew out of the Carlsberg Research Laboratory, has raised a €20m (about $22m) Series A led by Sofinnova Partners. It is the first outside capital the business has taken since it left the brewer, and it will pay for a push into the US and Australia, along with new work on algae and mushrooms.
The round matters beyond Denmark because of how Traitomic gets its results. Its traits come from variation that already exists in conventionally bred organisms, so customers can sell them as ordinary products. That lets them sidestep the approval rules that GM crops, and in many markets some gene-edited ones, still have to clear.
Joining Sofinnova were EIFO, the Danish state's export and investment fund, along with Nordic Foodtech VC, SVG Ventures, PSV Hafnium and Footprint Firm. ## From barley to 32 organisms
The technology behind the company is called FIND-IT. Carlsberg scientists originally built it to improve barley, the brewer's core crop. Instead of editing a genome, the platform screens large populations of plants or microbes that were bred the conventional way and picks out individuals carrying a specific genetic variant. One example the company gives is a tomato gene linked to sugar content.
That single organism then becomes the starting point for the customer's own breeding programme or production strain. Traitomic says it develops traits directly in the germplasm or strains its clients already sell, so the result lands in material they already have on the market.
Chief executive and co-founder Gustav Hambraeus said most trait-development methods are built for one kind of organism, often crops. Traitomic's is not.
"We can develop traits very, very fast, and we are not bound by specific organisms," Hambraeus said.
The company's own numbers support that claim, at least in breadth. So far it has delivered 116 traits to 47 customers, working across 32 organisms. Clients fall into three groups: plant breeding and seed companies; food supply chain and precision nutrition businesses; and biosolutions and industrial biotech firms. Projects have covered crop yield and robustness, drought tolerance, flavour, nutrition and shelf life in food, as well as the enzymes and microbial strains used in industrial fermentation.
Michael Krel, a partner at Sofinnova, said in the company's announcement that being able to build commercially relevant traits across such a wide range of organisms is rare in biology. Anders Røed, Carlsberg's executive vice president for group strategy and commercial, said the brewer would keep backing the spinout.
Where the €20m goes
Hambraeus said the round is mainly about commercial scale. Traitomic has kept a small footprint in both the US and Australia for roughly two years, and it now plans to grow both operations, including by hiring staff locally. The team today numbers more than 30 people, led by Hambraeus with co-founders Toni Wendt as technology lead and Jan Gottlieb as commercial lead.
Part of the money gives the company room to take on riskier work with clients. That includes new organism groups such as algae and mushrooms, and staying involved for longer on each project, from the first description of a business problem through to a trait that is ready to sell.
Hambraeus said the hard part is often not the idea but turning it into a trait, developing that trait and then confirming it produces the physical result the customer wanted. Each of those steps carries risk, he said, and Traitomic wants to carry clients further along that path than it does today.
A regulatory argument for the sector
For European agrifood investors, the pitch is a route to new traits that does not depend on how regulators eventually treat gene editing. Hambraeus is blunt about what that means for breeders and food companies.
"There are no excuses anymore for not doing trait development," he said, arguing that the company can work in any crop and bring results to market as conventional products.
The catch is that a delivered trait is not the same as a product on a supermarket shelf. Hambraeus said the real question for the next five or six years is whether customers actually commercialise them. The Series A buys Traitomic the people and the reach to find out, first in the US and Australia, and then in organisms it has not yet worked with.
What did you think of this story?
Written by
Mark T. Schwahn
57 stories on European Startup Insider
Have a story like this? Pitch it to us.
We publish founder profiles, company news and practical guides from across Europe.
More stories like this
Ex-H Company researchers raise $30m seed for Remanence to train custom models on agent data
Paris-based Remanence has raised a $30m seed round co-led by EQT Ventures and FirstMark to post-train open-weight models on the work its customers' AI agents already do. Datadog's Olivier Pomel and Synthesia's founders are among the angels.






